Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7259MR)

This product GTTS-WQ7259MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD), Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7259MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8430MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ9800MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ11318MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ12150MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ13290MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ15013MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ4425MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-663513
GTTS-WQ11418MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-8897
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW